[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350943-105":59,"doc-detail-350943-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","a-dually-nanobody-engineered-milk-derived-extracellular-vesicle-nanomedicine-targeting-tumour-associated-macrophages-and-cancer-cells-for-cancer-therapy","A Dually Nanobody-Engineered Milk-Derived Extracellular Vesicle Nanomedicine Targeting Tumour-Associated Macrophages and Cancer Cells for Cancer Therapy","","Tumour development and progression arise from complex cell–cell interactions in the tumour microenvironment (TME), and targeting one cell type often fails. MicroRNA-21-5p, abundant in tumour cells and tumour-associated macrophages (TAMs), drives cancer promotion. EGFR is frequently overexpressed and PD-L1 is mainly found on TAMs, supporting co-targeting strategies. This study builds dual-targeted engineered milk-derived extracellular vesicles (7D12/KN035-iEVs) for miR-21-5p inhibitor delivery to EGFR+ and/or PD-L1+ cells and TAMs, reprogramming immunosuppressive TME, with synergy alongside immunotherapy and radiotherapy.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-dually-nanobody-engineered-milk-derived-extracellular-vesicle-nanomedicine-targeting-tumour-associated-macrophages-and-cancer-cells-for-cancer-therapy/350943/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-dually-nanobody-engineered-milk-derived-extracellular-vesicle-nanomedicine-targeting-tumour-associated-macrophages-and-cancer-cells-for-cancer-therapy/350943.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-09","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",17,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is co-targeting multiple TME cell types important for cancer therapy?","Question",{"text":113,"@type":114},"Because interactions and “crosstalk” within the TME can limit the effectiveness of therapies aimed at only cancer cells or only other supportive cell types such as TAMs.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What is the purpose of using engineered milk-derived extracellular vesicles in this study?",{"text":118,"@type":114},"To deliver miR-21-5p inhibitors specifically into EGFR+ and/or PD-L1+ tumour cells and tumour-associated macrophages, thereby inhibiting tumour progression and reprogramming the immunosuppressive TME.",{"name":120,"@type":111,"acceptedAnswer":121},"Which molecular targets are used for dual targeting in the nanomedicine system?",{"text":122,"@type":114},"7D12 (an EGFR nanobody) and KN035 (a PD-L1 nanobody) are used to decorate the milk-derived extracellular vesicles for dual targeting.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},350943,1790164235,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Journal of Extracellular Vesicles  \nRESEARCH ARTICLE   \nA Dually Nanobody-Engineered Milk-Derived Extracellular Vesicle Nanomedicine Targeting Tumour-Associated Macrophages and Cancer Cells for Cancer Therapy  \nZhiang Liu1, 2  Ying Chen1, 2  Yulin Cao1, 2  Yanchao Zhang1, 2  Yuanben Wang1, 2  Han Cheng1, 2  Junhui Tang1, 2  Haofei Hong3  Yuyang Feng1, 2  Surui Yao1, 2  Zehua Bian1, 2   Yuan Yin1, 2   Kaisa Cui1, 2    \nZhimeng Wu3   Zhaohui Huang1, 2   \n1Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China  2 Laboratory of Cancer Epigenetics, Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, China  3Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, Jiangsu, China  \nCorrespondence: Zhaohui Huang ([zhaohuihuang@jiangnan.edu.cn](zhaohuihuang@jiangnan.edu.cn))  \nReceived: 15 May 2025  Revised: 6 January 2026  Accepted: 16 January 2026  \nKeywords: EGFR | milk-derived extracellular vesicle | miR-21-5p | nanobody | PD-L1 | tumour-associated macrophage  \nABSTRACT  \nTumour development and progression are driven by intricate interactions among various cell types within the tumour microenvironment (TME) . Targeting a single cell type often fails to eradicate cancer, highlighting the need for strategies to co-target multiple cell types. MicroRNA-21-5p, highly abundant in tumour cells and tumour-associated macrophages (TAMs), exerts strong cancer-promoting effects. Epidermal growth factor receptor (EGFR) is overexpressed in various cancer types, and programmed death-ligand 1 (PD-L1) is expressed predominantly by TAMs in multiple cancers. In this study, we developed a dualtargeted engineered milk-derived extracellular vesicles system (7D12/KN035-iEVs), decorated with 7D12 (an EGFR nanobody) and KN035 (a PD-L1 nanobody), to specifically deliver miR-21-5p inhibitors into EGFR+ and/or PD-L1+ tumour cells and TAMs, thereby inhibiting tumour progression while reprogramming immunosuppressive TME. Notably, this dual-targeting nanomedicine synergistically inhibits tumour growth when combined with immunotherapy and radiotherapy. In summary, this mEV-based nanomedicine represents a promising universal strategy for cancer treatment, offering a versatile platform for targeting multiple components ofthe TME.  \n1  Introduction  \nThe critical role of the tumour microenvironment (TME), particularly the inhibitory tumour immune microenvironment (TIME), in therapeutic resistance and cancer progression has been widely recognized (Li and Yin 2023) . In recent years, therapeutic strategies targeting the TME have emerged as promising approaches for cancer treatment (Xiao and Yu 2021) . However, accumulating evidence reveals that intricate ‘crosstalk’ between cancer cells and other cell types in the TME severely restricts the effectiveness of traditional therapies aimed at cancer cells or  \nother tumour-promoting noncancerous cell types like tumourassociated macrophages (TAMs) (Li and Yin 2023; Cui et al. 2024; Yin et al. 2017) . Furthermore, tumour heterogeneity plays a pivotal role in driving drug resistance and therapy failure by altering therapeutic targets or reprogramming the TME (Zhang et al. 2022) . Therefore, identification of common therapeutic targets in cancer cells and other cancer-promoting cell types in the TME and the design co-target strategies are urgently desired.  \nTAMs, a major noncancerous cell type in various solid tumours, play pivotal roles in tumour growth, drug resistance, angiogen-  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \n© 2026 The Author(s). Journal of Extracellular Vesicles published by Wiley Periodicals, LLC on behalf of the International Society for Extracellula","cbCaieHpWYEUFlu3","https://ap.wps.com/l/cbCaieHpWYEUFlu3","pdf",7070711,21,"English","# Abstract\n# Introduction\n## Tumour microenvironment and therapeutic resistance\n## TAM biology and repolarization\n## MicroRNAs in the TME\n# Open access and publication details","[{\"question\":\"Why is co-targeting multiple TME cell types important for cancer therapy?\",\"answer\":\"Because interactions and “crosstalk” within the TME can limit the effectiveness of therapies aimed at only cancer cells or only other supportive cell types such as TAMs.\"},{\"question\":\"What is the purpose of using engineered milk-derived extracellular vesicles in this study?\",\"answer\":\"To deliver miR-21-5p inhibitors specifically into EGFR+ and/or PD-L1+ tumour cells and tumour-associated macrophages, thereby inhibiting tumour progression and reprogramming the immunosuppressive TME.\"},{\"question\":\"Which molecular targets are used for dual targeting in the nanomedicine system?\",\"answer\":\"7D12 (an EGFR nanobody) and KN035 (a PD-L1 nanobody) are used to decorate the milk-derived extracellular vesicles for dual targeting.\"}]","A Dually Nanobody-Engineered Milk-Derived Extracellular Vesicle Nanomedicine Targeting Tumour-Associated Macrophages and Cancer Cells for Cancer Therapy | PDF",1790091935,53,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c506cb29563b4c85494c4a46551bb62e.webp",983,1291,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/25fb71b695fff0502c7f35dd33249ecc.webp",982,1290,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fced29e8c4ea3e7967a2389ed57079d1.webp",981,1289,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42816dca00245dca079525c655de593b.webp",980,1287]